title: The Effect of Bisphosphonates on Bone Mineral Density in Metastatic Prostate Cancer Patients Who Are Treated with Anti-Androgen Drugs and Radiotherapy.
abstract: OBJECTIVE
  To evaluate the potential effect of bisphosphonates on bone mineral density (BMD) in patients who are treated with anti-androgen drugs and radiotherapy for metastatic prostate cancer.
  
  
  METHODS
  The data of 31 patients with metastatic prostate cancer who were treated with anti-androgen drugs and radiotherapy during a 1-year period were retrospectively reviewed. Patients were divided in 2 groups, in which 17 patients in group 1 were treated with zoledronic acid (4 mg/month, intravenous) and 14 patients in group 2 who did not receive zoledronic acid. BMD was measured before the treatment and at the end of the 1st year by dual energy X-ray absorptiometry. Statistical analyses were performed with the T test.
  
  
  RESULTS
  Mean age of the patients was 71.42 ± 6.7(range 59-85) years. A significant increase was noted for pelvic bone, femoral neck, and lumbar vertebrae t scores when pretreatment and 1st year measurements were compared in group 1 (p < 0.05). In group 2 a significant decrease was noted for pelvic bone and femoral neck t scores at the end of the 1st year (p < 0.05). A significant increase was noted for pelvic bone and femoral neck follow-up in BMD values at the end of the 1st year compared to initial measurements in group 1. A significant decrease was noted for lumbar vertebrae follow-up in BMD values at the end of the 1st year when compared to initial values in group 2.
  
  
  CONCLUSIONS
  Zoledronic acid significantly increases BMD and delays unfavorable outcomes for bones in men who are treated with anti-androgen drugs and radiotherapy for metastatic prostate cancer.
authors.affiliation: Izmir University School of Medicine, Department of Urology, Izmir.
authors.forename: Ayhan
authors.initials: A
authors.lastname: Karaköse
authors.affiliation: Celal Bayar University School of Medicine, Department of Urology, Manisa, Turkey.
authors.forename: Mehmet B
authors.initials: MB
authors.lastname: Yüksel
authors.affiliation: Izmir University School of Medicine, Department of Urology, Izmir.
authors.forename: Özgü
authors.initials: Ö
authors.lastname: Aydoğdu
authors.affiliation: Celal Bayar University School of Medicine, Department of Urology, Manisa, Turkey.
authors.forename: Bilal
authors.initials: B
authors.lastname: Gümüş
authors.affiliation: Izmir University School of Medicine, Department of Urology, Izmir.
authors.forename: Yusuf Z
authors.initials: YZ
authors.lastname: Ateşçi
authors.affiliation: Celal Bayar University School of Medicine, Department of Biopysics, Manisa, Turkey.
authors.forename: Zafer
authors.initials: Z
authors.lastname: Akan
keywords: Bisphosphonate therapy; Metastatic prostate cancer; Osteoporosis; Radiotherapy